Contact

News & Events

Recent News & Events

Featured
Apr 06, 2017
WPLG-TV
New detection method could help identify oral cancer sooner

Vigilant Biosciences’ Scientific Co-Founder and Chief Scientific Officer Elizabeth Franzmann, M.D., recently caught up with WPLG to discuss oral cancer and the Company’s OncAlert Oral Cancer product line.

March 30, 2017
Oral Cancer Awareness Survey Reveals 81 Percent of U.S. Adults Want to Be Screened for Oral Cancer During Routine Dental Check-ups; Only 29 Percent Actually Are

Survey conducted by Vigilant Biosciences, Head and Neck Cancer Alliance, Oral Cancer Foundation and Support for People with Oral and Head and Neck Cancer reveals low awareness, misconceptions and desire for more information on oral cancer

Feb 02, 2017
Fort Lauderdale Magazine
Ever Vigilant: A Fort Lauderdale company is becoming an international leader in oral cancer prevention.

For Matthew Kim, the idea for his company came when he was taking his mother to doctor visits for her cancer treatments. She was on her third battle with oral cancer, while Kim had a consulting firm and the fortunate flexibility to take her to her chemotherapy, radiation and rehabilitation.          

Media Coverage
Vigilant Biosciences Inc, Fort Lauderdale, Fla, has launched patient enrollment for clinical studies of its OncAlert point-of-care qualitative assay in support of its premarket regulatory submission to FDA.
Oral and throat cancers can be life-threatening, and their frequency seems to be increasing. Now, two tests that are simple, painless and noninvasive can often detect them at very early stages when they can often be treated successfully.
Fort Lauderdale-based Vigilant Biosciences, which has developed dental and lab toolkits for early detection of oral cancer, has been awarded part of a multi-million dollar grant for a study from the National Institutes of Health.
Vigilant Biosciences has initiated a US FDA clinical study, with plans to recruit up to 1,000 patients, of its OncAlert point-of-care oral cancer risk assessment test.
The OncAlert oral cancer product line from Vigilant Biosciences Inc., Fort Lauderdale, Fla, includes the OncAlert oral cancer rapid test and the OncAlert oral cancer lab test, available in countries accepting CE mark.
Oral cancer – including cancers of the mouth and throat – is an area that is attracting new attention from the diagnostic community – this time with the help of dentists.
Vigilant Biosciences has launched patient enrollment for clinical studies of its OncAlert point-of-care qualitative assay in support of its registration submission to the Food and Drug Administration (FDA).
Nearly 50,000 people are diagnosed with oral cancer in the U.S. each year—and that number continues to grow, particularly among certain segments of the population.
More than 49,750 people in the United States will be diagnosed with oral cancer this year, according to Vigilant Biosciences. Yet 62% of adults in the US know very little or nothing at all about the disease—including cancer of the oral cavity, tongue, larynx, and pharynx—and only 29% report being screened for oral cancer at […]
View More
Press Releases
Company to exhibit as Bronze Sponsor of IFOS ENT World Congress and present interim analysis of European clinical studies in support of its OncAlert Oral Cancer product line
Grant to fund multi-institutional study on rapid, point-of-care test to aid in the early identification of oral and oropharyngeal cancer
Company begins drive toward FDA clearance of first and only test to detect a tumor-initiating stem cell-associated biomarker for oral and oropharyngeal cancer
Survey conducted by Vigilant Biosciences, Head and Neck Cancer Alliance, Oral Cancer Foundation and Support for People with Oral and Head and Neck Cancer reveals low awareness, misconceptions and desire for more information on oral cancer
Vigilant Biosciences, Inc. today announced the acceptance of five abstracts regarding data related to studies conducted by the Company to better understand the performance characteristics of a combined salivary CD44 and total protein assay as an aid in the diagnosis of head and neck squamous cell carcinoma (HNSCC).The studies, along with others, helped provide direction for […]
Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, will showcase its OncAlert® Oral Cancer product line in Hall 5.1, Stand: D069 at the 37th International Dental Show (IDS), the world’s leading tradeshow for the dental industry, being held March 21-25, 2017 in Cologne, […]
Matthew H.J. Kim, Founder, Chairman and CEO at Vigilant Biosciences, will present a poster on the study, “Multivariate oral rinse models predict Head and Neck squamous cell carcinoma (HNSCC),” at the 6th International Conference on Innovative Approaches in Head and Neck Oncology (ICHNO), from March 16-18, 2017, in Barcelona, Spain.      
Matthew H.J. Kim, Founder, Chairman and Chief Executive Officer at Vigilant Biosciences, will present at two upcoming conferences in San Francisco: the BioLink 2017 China Healthcare Industry Investment and Licensing Conference, taking place January 8, 2017 at the San Francisco Hilton Airport Hotel, and Medtech Showcase 2017 (at Biotech Showcase™), taking place at the Parc 55 San Francisco, January 10 – 11, […]
Vigilant Biosciences today announced exclusive multi-year distribution agreement for sales and marketing of its OncAlert® Oral Cancer product line in Spain, Portugal and Germany. The Company made the announcement in conjunction with the MEDICA Trade Fair, where the Company is showcasing its OncAlert Oral Cancer product line in Hall 16, booth #D04.      
View More
Events
August 29 – September 1, 2017
October 9 – 14, 2017
November 13 – 16, 2017
November 24 – 29, 2017
View More

MEDIA INQUIRIES

Jennifer Moritz
Zer0 to 5ive
jmoritz@0to5.com
917.748.4006

INVESTMENT INQUIRIES

Paula Schwartz
Rx Communications Group, LLC
pschwartz@rxir.com
917.322.2216